**Suppl. Table 2.** Concentrations of docetaxel, paclitaxel, vinblastine, vinflunine, cabazitaxel, larotaxel, doxorubicin, methotrexate, and gemcitabine that reduce TCC-SUP, TCC-SUPrGEMCI20, TCC-SUPrVBL20, TCC-SUPCER2, and TCC-SUPABCB1 cell viability by 50% (IC50).

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Zosuquidar | Docetaxel | Paclitaxel | Vinblastine | Vinflunine |
| Cell line | 1.25 µM | IC50 (ng/mL) | IC50 (ng/mL) | IC50 (ng/mL) | IC50 (ng/mL) |
| TCC-SUP | - | 0.37 ± 0.24 | 2.65 ± 1.35 | 0.50 ± 0.28 | 25.99 ± 16.37 |
| TCC-SUP | + | 0.37 ± 0.23(1.00)\* | 2.06 ± 1.05(1.28) | 0.52 ± 0.28(0.96) | 23.81 ± 14.89(1.09) |
| TCC-SUPrGEMCI20 | - | 1.59 ± 0.79 | 13.62 ± 3.27 | 3.11 ± 1.71 | 48.23 ± 29.40 |
| TCC-SUPrGEMCI20 | + | 0.40 ± 0.27(3.97) | 4.36 ± 1.22(3.12) | 1.00 ± 0.86(3.11) | 24.94 ± 13.08(1.93) |
| TCC-SUPrVBL20 | - | 30.79 ± 3.30 | 156.80 ± 19.19 | 26.92 ± 6.17 | 439.19 ± 230.85 |
| TCC-SUPrVBL20 | + | 0.34 ± 0.12(90.55) | 0.71 ± 0.11(220.84) | 0.65 ± 0.22(41.47) | 18.66 ± 6.84(23.53) |
| TCC-SUPCER2 | - | 0.41 ± 0.28 | 1.79 ± 0.55 | 0.20 ± 0.04 | 14.73 ± 4.88 |
| TCC-SUPCER2 | + | 0.38 ± 0.35(1.07) | 1.30 ± 0.25(1.37) | 0.18 ± 0.02(1.11) | 10.92 ± 3.00(1.35) |
| TCC-SUPABCB1 | - | 10.21 ± 1.80 | 78.88 ± 8.85 | 6.22 ± 0.41 | 51.73 ± 35.52 |
| TCC-SUPABCB1 | + | 0.23 ± 0.12(44.39) | 0.87 ± 0.13(90.66) | 0.14 ± 0.13(44.42) | 5.87 ± 0.95(8.81) |

\*Resistance factor: IC50 of tested cell line (w/o zosuquidar)/ IC50 of tested cell line (+ 1.25µM zosuquidar). Values are means ± SD.

**Suppl. Table 2.** **(continued)** Concentrations of docetaxel, paclitaxel, vinblastine, vinflunine, cabazitaxel, larotaxel, doxorubicin, methotrexate, and gemcitabine that reduce TCC-SUP, TCC-SUPrGEMCI20, TCC-SUPrVBL20, TCC-SUPCER2, and TCC-SUPABCB1 cell viability by 50% (IC50).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Zosuquidar | Cabazitaxel | Larotaxel | Doxorubicin | Methotrexate | Gemcitabine |
| Cell line | 1.25 µM | IC50 (ng/mL) | IC50 (ng/mL) | IC50 (ng/mL) | IC50 (ng/mL) | IC50 (ng/mL) |
| TCC-SUP | - | 0.20 ± 0.01 | 1.15 ± 0.02 | 8.79 ± 1.19 | 4.55 ± 2.18 | 0.66 ± 0.40 |
| TCC-SUP | + | 0.20 ± 0.01(1.00)\* | 1.15 ± 0.01(1.00) | 8.84 ± 2.75(0.99) | 3.90 ± 1.92(1.16) | 0.82 ± 0.39 (0.80) |
| TCC-SUPrGEMCI20 | - | 1.05 ± 0.05 | 1.83 ± 0.05 | 89.05 ± 28.04 | 24.24 ± 11.60 | 104.81 ± 47.04 |
| TCC-SUPrGEMCI20 | + | 1.61 ± 0.09(0.65) | 1.60 ± 0.06(1.14) | 66.00 ± 25.87(1.34) | 20.81 ± 7.98(1.16) | 93.49 ± 67.02(1.12) |
| TCC-SUPrVBL20 | - | 1.07 ± 0.01 | 2.91 ± 0.16 | 197.96 ± 84.39 | 22.10 ± 0.13 | 1.61 ± 0.27 |
| TCC-SUPrVBL20 | + | 0.24 ± 0.01(4.45) | 1.40 ± 0.25(2.07) | 17.23 ± 2.84 (11.48) | 20.90 ± 2.35(1.05) | 1.91 ± 0.31(0.84) |
| TCC-SUPCER2 | - | 0.48 ± 0.34 | 1.65 ± 0.09 | 21.47 ± 9.47 | 1.77 ± 0.68 | 1.31 ± 0.35 |
| TCC-SUPCER2 | + | 0.45 ± 0.39(1.06) | 1.41 ± 1.16(1.17) | 16.03 ± 8.82(1.33) | 1.52 ± 0.97(1.16) | 1.78 ± 0.37(0.73) |
| TCC-SUPABCB1 | - | 0.64 ± 0.36 | 2.54 ± 1.22 | 930.12 ± 202.20 | 2.39 ± 0.67 | 1.01 ± 0.15 |
| TCC-SUPABCB1 | + | 0.10 ± 0.05(6.40) | 1.09 ± 0.90(2.33) | 46.51 ± 15.50(19.99) | 2.10 ± 0.75(1.13) | 1.61 ± 0.16(0.62) |

\*Resistance factor: IC50 of tested cell line (w/o zosuquidar)/ IC50 of tested cell line (+ 1.25µM zosuquidar). Values are means ± SD.